Diligence memo · auto-generated · as of July 2, 2026
C19 Corp.
C19 Corp. looks fair against its niche peers and is dormant on financing cadence.
Businessfiled
C19 Corp. operates in Biotechnology, based in HAUPPAUGE.
No verified homepage on file yet — operating evidence is limited to the public record.
Capital & rounds (filed)filed
C19 Corp. has raised $33M in disclosed capital across 3 recorded rounds, aggregated from public filings. Its latest round is modeled as Series B (a $15M–$40M round).
Largest single filing: $18M on 2020-08-07.
Most recent recorded round closed around 2020-08-07.
Valuation (modeled)modeled
Provath models C19 Corp. at approximately $685M (range $36M–$2.6B). This is an algorithmic estimate from round sizes and same-niche peers — not a quoted or reported figure.
Read: Fair. Modeled value is 1.11× the median modeled value of Series B Biotechnology companies in 2019–2021 (118 peers) — value vs value, same stage and era. Within the normal band (111% of peer median) for its niche.
Financing rhythm & timingmixed
Historic cadence: a new round about every 2 months.
Last raise 5.9 yr ago; this sector typically re-raises about every 14 months.
Silent for over 3× the sector's normal cadence.
The last round stepped up 1.7× from the prior — scaling.
Comparablesmixed
Capital scale ranks ahead of 76% of Biotechnology peers (4293 compared).
Modeled value ranks above 86% of those peers.
Closest niche peers: Pandion Therapeutics Holdco LLC, Ocular Therapeutix, Inc, Insilico Medicine Cayman TopCo, Purigen Biosystems, Inc., Lucira Health, Inc..
Peoplefiled
4 named people on file across officers, directors and signatories.
Risks & flagsmixed
Financing has been silent well beyond sector cadence — possibly defunct, acquired, or paused.
No clearly named CEO/founder/principal in the surfaced records — key-person evidence is thin.